Bolt Biotherapeutics Inc - Company Profile
Powered by 
All the data and insights you need on Bolt Biotherapeutics Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Bolt Biotherapeutics Inc Strategy Report
- Understand Bolt Biotherapeutics Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Bolt Biotherapeutics Inc (Bolt Biotherapeutics) is a clinical-stage biopharmaceutical company that develops novel immunotherapies for the treatment of cancer. The company develops immuno-oncology therapeutics by using the Boltbody ISAC platform. Its pipeline products include BDC-1001 and BDC-3042. Its BDC-1001 product treats HER2-positive colorectal, endometrial, gastroesophageal and metastatic breast cancer. Bolt Biotherapeutics’ BDC-3042 product treats solid tumors. Its Boltbody ISAC platform works in collaboration with Genmab A/S, Innovent Biologics, Inc and Toray Membrane USA, Inc. Bolt Biotherapeutics is headquartered in Redwood City, California, the US.
Headquarters
United States of America
Address
900 Chesapeake Drive, Redwood City, California, 94063
Website
boltbio.com
Telephone
1 650 6659295
No of Employees
100
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
BOLT (NASD)
Revenue (2022)
$7.9M
37.5%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
21.5%
(2022 vs 2021)
Market Cap*
$44.2M
Net Profit Margin (2022)
XYZ
42.9%
(2022 vs 2021)
* As of and is in US$
Bolt Biotherapeutics Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Pipeline | Boltbody |
| BDC-1001: Colorectal Cancer, Endometrial Cancer, Gastroesophageal Cancer and Metastatic Breast Cancer | |
| BDC-3042: Solid Tumors |
Competitor Comparison
| Key Parameters | Bolt Biotherapeutics Inc | F. Hoffmann-La Roche Ltd | Novartis AG | AstraZeneca Plc | Daiichi Sankyo Co Ltd |
|---|---|---|---|---|---|
| Headquarters | United States of America | Switzerland | Switzerland | United Kingdom | Japan |
| City | Redwood City | Basel | Basel | Cambridge | Chuo-Ku |
| State/Province | California | - | - | England | Tokyo |
| No. of Employees | 100 | 103,605 | 76,057 | 89,900 | 17,435 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Randall C. Schatzman, Ph.D. | Chief Executive Officer; Director | Executive Board | 2019 | 68 |
| William P. Quinn | Chief Financial Officer | Senior Management | 2020 | 52 |
| Edith A. Perez, M.D. | Chief Medical Officer | Senior Management | 2020 | 66 |
| Wesley Burwell | Vice President; Head - Human Resources | Senior Management | 2021 | - |
| John Tomaro | Vice President - Clinical Operations | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer